On the eve of Boston Biotech Week, a report was released by MassBio that claimed 48% of all biotech investment in 2017 was accounted for by Massachusetts-based companies.
Biotech M&A started off a bang this year and as the first half of the year has drawn to a close, biotech IPOs have reached a number that could see 2018 become a record-breaker.